Participant flow14

How many started, completed or left each group, period by period.

1 to 14 of 14

Period	Milestone	Group	Participants
Overall Study	STARTED	Lapatinib (LTax/L)	326
Overall Study	STARTED	Trastuzumab (TTax/T)	326
Overall Study	Randomized Not Treated	Lapatinib (LTax/L)	4
Overall Study	Randomized Not Treated	Trastuzumab (TTax/T)	1
Overall Study	Crossed Over to Ttax/T After IA Results	Lapatinib (LTax/L)	5
Overall Study	Crossed Over to Ttax/T After IA Results	Trastuzumab (TTax/T)	0
Overall Study	Central HER2 Positive	Lapatinib (LTax/L)	270
Overall Study	Central HER2 Positive	Trastuzumab (TTax/T)	267
Overall Study	Safety Population	Lapatinib (LTax/L)	322
Overall Study	Safety Population	Trastuzumab (TTax/T)	325
Overall Study	COMPLETED	Lapatinib (LTax/L)	0
Overall Study	COMPLETED	Trastuzumab (TTax/T)	0
Overall Study	NOT COMPLETED	Lapatinib (LTax/L)	326
Overall Study	NOT COMPLETED	Trastuzumab (TTax/T)	326

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00667251/flow